TickerFacts.

NeuroSense Therapeutics Ltd. (NRSN): Capital Expenditures

Annual figures by period end, from SEC filings.

$8.0K
Year ended 2025-12-31
-51.5%
3-year compound annual growth
$70.0K2022-12-31: $70.0K2023-12-31: $29.0K2024-12-31: $3.0K2025-12-31: $8.0K$8.0K
2022-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$8.0K+166.7%2026-03-31, From 2025-01-01
2024-12-31$3.0K-89.7%2026-03-31, From 2024-01-01
2023-12-31$29.0K-58.6%2026-03-31, From 2023-01-01
2022-12-31$70.0Kn/a2025-04-07, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
NeuroSense Therapeutics Ltd. (NRSN)2025-12-31$8.0K+166.7%
Vaccinex, Inc. (VCNX)2024-12-31$22.0K-67.2%
Polomar Health Services, Inc. (PMHS)2024-12-31$90.9Kn/a
Neonc Technologies Holdings, Inc. (NTHI)2025-12-31$500.0Kn/a
Bespoke Extracts, Inc. (BSPK)2024-12-31$600.0Kn/a
Alaunos Therapeutics, Inc. (TCRT)2025-12-31$98.0Kn/a
Protagenic Therapeutics, Inc.\new (PTIX)2026-03-31$3.3Kn/a
Pulmatrix, Inc. (PULM)2024-12-31$398.0K-41.1%
Lexaria Bioscience Corp. (LEXX)2025-08-31$24.6K-42.7%

Compare NRSN, VCNX, PMHS, NTHI side by side · Screen every company in Pharmaceutical Preparations ↗